Development of Quinazoline/Pyrimidine-2,4(1 H ,3 H )-diones as Agonists of Cannabinoid Receptor Type 2.

Starting from a prototypical structure , we describe our efforts to design and obtain novel quinazoline/pyrimidine-2,4(1,3)-diones with high CB2 agonist potency and selectivity as well as improved physicochemical characteristics, mainly hydrophilicity. The most potent and selective CB2 agonists, and , in this series were also endowed with lower logP values than that of GW842166X and lead compound . These derivatives appear to be promising lead compounds for the development of future CB2 agonists.